Influx HealthtechShare price, financial results, shareholding and management
- Market cap
- ₹644 cr
- Stock P/E
- 31.3peers 21.3
- Book value
- ₹43.5
- Price to book
- 6.39
- EV / operating profit
- 20.7
- Market cap to sales
- 4.38
- ROCE · FY26
- 40.1%
- ROE · FY26
- 30.0%
- ROE, 3-year average
- 45.6%
- Operating margin · FY26
- 20.3%peers 8.9%
- Sales growth, 3 years
- 24.5%
- Profit growth, 3 years
- 43.2%
- Debt to equity
- 0.00peers 0.48
- Borrowings
- ₹0 cr
- Interest cover
- 152.3×
- Cash from business / op. profit
- 13%
- Debtor days
- 84
- Pledged
- 0.00%
- Promoter holding
- 73.53%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 1,335
- 52-week high / low
- ₹315 / ₹183
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Influx Healthtech share price chart
Close on 19 Nov 2026 · -0.32% on the day · Vol 14,400
Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 19 Nov 2026
- 1 month
- +7.2%
- 3 months
- -3.6%
- 6 months
- +19.2%
- 1 year
- +21.3%
- Since IPO
- +189.7%
- Traded a day, 20 days
- ₹0.59 cr
- Taken for delivery
- 78%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +40% | +58% |
| 3 years, a year | +25% | +43% |
| Latest half, H2 FY26 | +40% | +32% |
About Influx Healthtech: business, products and customers
Influx Healthtech makes health supplements, and some skin care, herbal, pet and home care products, for other companies that put their own brand names on them. It works from factories in Palghar, Maharashtra, and its shares trade on NSE Emerge.
Influx Healthtech is a contract maker: brand owners, from multinationals to young online brands, bring a product idea and the company develops the formula, makes it and handles the regulatory work. It offers tablets, capsules, powders, gummies, protein bars, liquids and sachets, and lists more than 3,400 products.
Nutraceuticals brought in 90% of FY26 revenue, with cosmetics, ayurvedic products and a small veterinary and home care line making up the rest. Production runs from four units in Palghar, one of them rented, holding certifications such as GMP, HACCP, Halal, ISO 22000 and NSF. Almost all sales are in India.
Read more about the business
What is new: a nutraceutical plant of about 75,000 sq ft on Plot No. 59, paid for from the June 2025 public issue, which the company says will lift installed capacity about two and a half times. It has also set up a subsidiary, Olahey Wellness, for ready to drink beverages, ordered a larger pet food line and received approvals to supply Tanzania and Nigeria.
From the offer document (red herring prospectus, June 2025), the annual report 2024-25, the May 2026 investor presentation and earnings call, and the April 2026 press release on the use of issue proceeds.
Read the deeper study ↓In its favour
- Sales have grown fast: 25% a year over three years.
- It earns a high return on the money it uses: ROCE 40% in FY26.
- It has little debt for its size: debt to equity 0.00.
- The promoters own a large part of the company: 73.53%.
To watch
- Start of the Plot No. 59 nutraceutical plant, which the managing director expected to be ready by July or August 2026 (Earnings call, May 2026, p.3 to 5; Press release, April 2026, p.4).
- FY27 revenue growth against the company's guidance of 25% to 30% with similar margins (Investor presentation, May 2026, p.5).
- The beverage line at Olahey Wellness and the 1,000 kg per hour pet food line, both ordered for FY27 (Investor presentation, May 2026, p.20; Earnings call, May 2026, p.4).
- Share of revenue from the ten largest clients, 49% in FY26 (Investor presentation, May 2026, p.29).
- Customers take longer to pay than before: 84 days in FY26, against 64 in FY22.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Influx Healthtech revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.
Influx Healthtech half-yearly results
SME companies report every six months · ₹ crore
| H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|
| Sales | 48 | 57 | 66.76 | 80.07 |
| Expenses | 39 | 45 | 52.10 | 64.87 |
| Operating profit | 9 | 11 | 14.66 | 15.20 |
| OPM | 19.0% | 20.0% | 22.0% | 19.0% |
| Interest | 0 | 0 | 0 | 0.18 |
| Depreciation | 1 | 2 | 1.68 | 2.09 |
| Profit before tax | 8 | 10 | 13.07 | 14.16 |
| Net profit | 6 | 8 | 10.01 | 10.55 |
Influx Healthtech profit and loss
Full years to March, FY22 to FY26 · ₹ crore, consolidated where reported
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Sales | 59 | 76 | 100 | 105 | 146.83 |
| Expenses | 53 | 65 | 83 | 84 | 116.98 |
| Operating profit | 6 | 11 | 17 | 21 | 29.86 |
| OPM | 11.0% | 14.0% | 17.0% | 20.0% | 20.3% |
| Other income | 0 | 0 | 0 | 0 | 1.33 |
| Interest | 0 | 0 | 0 | 0 | 0.18 |
| Depreciation | 0 | 1 | 2 | 3 | 3.78 |
| Profit before tax | 6 | 10 | 15 | 18 | 27.23 |
| Tax rate | 33.3% | 30.0% | 26.7% | 27.8% | 24.6% |
| Net profit | 4 | 7 | 11 | 13 | 20.54 |
| EPS ₹ | 1,800 | 2,880 | 4,452 | 7.37 | 9.35 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
The years to FY25 come rounded to the nearest crore in the source.
Earnings per share before FY25 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.
Influx Healthtech profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a high return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Operating margin | 11.0% | 14.0% | 17.0% | 20.0% | 20.3% |
| Tax rate | 33.3% | 30.0% | 26.7% | 27.8% | 24.6% |
| ROCE | · | 110.7% | 83.2% | 61.0% | 40.1% |
| ROE | · | 87.2% | 62.7% | 44.0% | 30.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Influx Healthtech debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. It has almost no borrowings. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Influx Healthtech balance sheet
At each 31 March · ₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Equity capital | 0.03 | 0.03 | 0.03 | 18 | 23.15 |
| Reserves | 4 | 12 | 23 | 18 | 77.61 |
| Net worth | 4.03 | 12.03 | 23.03 | 36 | 100.76 |
| Borrowings | 1 | 1 | 0 | 0 | 0 |
| Other liabilities | 12.97 | 14.97 | 17.97 | 34 | 22.94 |
| Total liabilities | 18 | 28 | 41 | 70 | 123.70 |
| Fixed assets | 3 | 6 | 14 | 19 | 27.58 |
| Capital work in progress | 0 | 0 | 0 | 0 | · |
| Investments | 0 | 0 | 0 | 0 | 2.30 |
| Other assets | 15 | 22 | 27 | 51 | 93.82 |
| Receivables | · | · | · | · | 33.78 |
| Inventory | · | · | · | · | 15.93 |
| Cash | · | · | · | · | 25.17 |
| Trade payables | · | · | · | · | 19.12 |
Influx Healthtech cash flow
₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Cash from operations | 4 | 7 | 9 | 7 | 3.89 |
| Cash from investing | -3 | -5 | -8 | -9 | -25.16 |
| Cash from financing | 1 | 0 | -1 | 0 | 44.53 |
| Net cash flow | 2 | 2 | 0 | -2 | 23.26 |
| Capital spending | · | · | · | · | 24.56 |
Working capital
Days
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Debtor days | 64 | 66 | 58 | 113 | 84 |
| Inventory days | 14 | 18 | 41 | 112 | · |
| Days payable | 88 | 123 | 106 | 248 | · |
| Cash conversion cycle | -10 | -39 | -6 | -24 | · |
| Working capital days | 2 | 1 | 15 | 46 | · |
Influx Healthtech peers and competitors
Listed SME companies in the same industryBy sales, Influx Healthtech is number 8 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Infinium Pharmachem | 471 | 38.7 | 190 | 12.2 | 11.4% | 0.19 |
| Zenith Drugs | 68 | 17.2 | 171 | 3.9 | 7.1% | 0.75 |
| Mono Pharmacare | 16 | 44.6 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 644 | 31.3 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Quest Laboratories | 154 | 10.3 | 112 | 15 | 16.3% | 0.08 |
| KRM Ayurveda | 573 | 28.6 | 102 | 20 | 30.0% | 0.00 |
| Median of the 10 others | 111 | 21.3 | 130 | 5.7 | 8.9% | 0.48 |
Influx Healthtech shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Foreign and Indian funds own a noticeable share. The number of shareholders has come down.
Influx Healthtech shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Jun 25 | Sep 25 | Mar 26 | |
|---|---|---|---|
| Promoters | 73.53% | 73.53% | 73.53% |
| Foreign investors (FIIs) | 3.38% | 1.83% | 0.16% |
| Indian institutions (DIIs) | 10.46% | 6.83% | 5.65% |
| HNIs (over ₹2 lakh each) | 0.00% | 5.64% | 6.53% |
| Small holders (up to ₹2 lakh) | 10.89% | 8.28% | 9.60% |
| Companies and others | 1.74% | 3.89% | 4.53% |
| Number of shareholders | 2,403 | 1,022 | 1,335 |
The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.
Influx Healthtech study: the business from its own documents
Read from 11 of the company's own documentsInflux Healthtech so far
From the company's own record
- 25 June 2025Listed on NSE Emerge at ₹96
- 31 March 2026Promoters at 73.53%
- 6 July 2026Highest close since listing, ₹312.35
Influx Healthtech key facts from the filings
Each figure with the document it comes from
- Revenue growth
- 40%
- FY26 revenue rose to ₹146.8 cr from ₹104.9 cr, after only about 5% growth in FY25 when the plants were running at full capacity.Investor presentation, May 2026, p.31; Annual report 2024-25, p.53
- Top ten clients
- 49%
- Share of FY26 revenue from the ten largest clients, about the same as in the two years before.Investor presentation, May 2026, p.29
- Clients served
- 718
- Number of clients in FY26, up from 636 in FY25; the company puts client retention at 98%.Investor presentation, May 2026, p.4 and p.16; Earnings call, May 2026, p.4
- Capacity used
- 70%
- Share of capacity in use in FY26 after new lines were added, against 89% in FY25.Investor presentation, May 2026, p.4
- New plant
- 75,000 sq ft
- Nutraceutical facility on Plot No. 59, enlarged from about 35,000 sq ft; the managing director said in May 2026 it should be ready by July or August 2026.Earnings call, May 2026, p.3 to 5; Press release, April 2026, p.3
Show 5 more facts
- Issue money used
- 45.6%
- Share of the ₹43.4 cr of issue proceeds for stated objects used by 31 March 2026; ₹10.1 cr was moved from the veterinary plant and machinery to the nutraceutical building.Press release, April 2026, p.2
- Cash from operations
- ₹3.9 cr
- Operating cash flow in FY26 against profit after tax of ₹20.5 cr, as trade payables fell by ₹10.3 cr.Investor presentation, May 2026, p.31 and p.33
- Second half margin
- 19.0%
- EBITDA margin in the second half of FY26, down from 20.2% a year earlier, as material costs and new hires rose.Investor presentation, May 2026, p.31; Earnings call, May 2026, p.4 and p.8
- Product range
- 3,428
- Products made in FY26, across supplements, cosmetics, ayurvedic, veterinary and home care lines.Investor presentation, May 2026, p.4
- Borrowings
- Nil
- No borrowings at March 2026, with cash of ₹25.2 cr; the managing director said no debt is planned for the expansion.Investor presentation, May 2026, p.32; Earnings call, May 2026, p.21 and p.22
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company guides for FY27 revenue growth of 25% to 30% with similar margins. On the May 2026 call, Managing Director Munir Chandniwala said the new Plot No. 59 plant should be ready by July or August 2026, that it could add about ₹40 cr to ₹50 cr of revenue in FY27, and that the company aims for revenue of about ₹450 cr to ₹500 cr by FY29. The April 2026 press release said the enlarged construction should finish within about 180 days of shareholder approval.
| What management said | When | What happened |
|---|---|---|
| A sharp rise in orders in FY26, with stock built in March 2025 for it | Annual report 2024-25 | FY26 revenue up 40%, to ₹146.8 cr |
| Capacity raised 25% to 30% before using issue proceeds | May 2026 presentation | Capsule, tablet and liquid lines added in H1 FY26 from internal accruals |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Influx Healthtech earns its money making supplements and other health products to order for brand owners, and has kept steady margins while growing.
Its weak spots are a handful of large clients who bring in about half the sales and push for lower prices, and a big new plant that still has to be filled.
AverageCan it set its own prices?Prices are set on a cost plus basis, so higher material costs are passed on, but only after a lag, and large clients pay thinner margins.
AverageHow strong is it against rivals?Its strengths are a very wide product range, small and large batch sizes and in house design, regulatory and printing support, but the documents give no market share.
WatchWho are its customers?Hundreds of brand owners, most of whom stay, but the ten largest bring in about half the revenue.
AverageDoes it need a lot of money?Growth needs new plants and machines, which the issue money is paying for, and in FY26 little of the profit turned into cash.
AverageCan it keep finding new work?There are no long term contracts, so work comes order by order, though existing clients keep growing and new names keep joining.
AverageDo good and bad years swing a lot?Demand for supplements has been steady, but growth stalls when the plants are full and margins move with material costs and the client mix.
Who runs Influx Healthtech?
Promoters, directors and officers; tap a name for the background
MAMunir Abdul Ganee ChandniwalaPromoter, Chairman and Managing Director · holds 69.73%
Founder of the company. Holds a Bachelor of Pharmacy from the University of Pune, a post graduate degree in Management and Business Administration and a Doctor of Philosophy programme, and is a registered pharmacist with the Maharashtra State Pharmacy Council. About 22 years in nutraceutical, cosmetic, ayurvedic and home care manufacturing; ran Influx Healthcare, a sole proprietorship in third party manufacturing, from 2002.
Offer document, p.228, p.241 and p.247; Investor presentation, May 2026, p.23SMShirin Munir Ahmed ChandniwalaPromoter and Whole-Time Director · holds 3.80%
Co-founder with a Bachelor of Commerce from Hemchandracharya North Gujarat University and more than 12 years in trading of packaging materials, as a partner of Shinaf Enterprise since 2012. Looks after financial management, data analysis and budgets. The offer document states that Shirin Munir Ahmed Chandniwala is the spouse of Munir Abdul Ganee Chandniwala.
Offer document, p.228 to 230 and p.247AGAbdul Ganee Abdul Rasul ChandniwalaPromoter and Non-Executive Director
Holds a Diploma of Licentiate of the Court of Examiners of Homeopathic and Biochemic Systems of Medicine and a certificate in Modern Pharmacology, with about 21 years in the pharmaceutical industry. The offer document states that Abdul Ganee Abdul Rasul Chandniwala is the father of Munir Abdul Ganee Chandniwala, and notes that the company could not document earlier years of experience.
Offer document, p.229, p.230 and p.247VBVipul Balubhai PatelIndependent Director
A doctor with an MBBS and an MD in Pathology, a member of the Maharashtra Medical Council, and founder director of Sunflower Laboratory & Diagnostic Center in Mumbai since 1998; 26 years in healthcare.
Offer document, p.229; Investor presentation, May 2026, p.23MSMohmad Saleh MutvalliIndependent Director
A Chartered Accountant and member of ICAI with experience in taxation, accounting and compliance, listed as an Independent Director in the May 2026 investor presentation.
Investor presentation, May 2026, p.23AGAshish Ghanshyam ShahChief Financial Officer
Bachelor of Commerce from the University of Mumbai with more than 20 years in accounts and finance, including work at Konark Synthetic; Chief Financial Officer since May 2024.
Offer document, p.229, p.241 and p.242Influx Healthtech latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹80.1 cr (+40%), net profit ₹10.6 cr (+32%) on H2 FY25.
- Shareholding, 31 March 2026: promoters unchanged at 73.53%; Aarth AIF Growth Fund down to 1.40%.
Influx Healthtech announcements
83 on record, latest first; each opens the filing on the exchange
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- General UpdatesImposition of Fine by NSE LtdPDF ↗
- Analysts/Institutional Investor Meet/Con. Call UpdatesSchedule of Analyst / Institutional Investor meetingsPDF ↗
- Shareholders meetingof the Scrutiniser s Report and Voting Results of its 6th Annual General Meeting held on September 18, 2026PDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 18, 2026PDF ↗
- Updates'Dispatch of Letters to Shareholders under Regulation 36(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015'PDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
- Shareholders meetingNotice of Annual General Meeting to be held on September 18, 2026PDF ↗
- Outcome of Board MeetingHeld on August 26, 2026PDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018For quarter ended on June 30, 2026PDF ↗
Influx Healthtech annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
- 31 May 2026 ↗read
- 30 Nov 2025 ↗read
- 31 Aug 2025 ↗read
Influx Healthtech share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Influx Healthtech's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (2,31,50,400 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- !Earnings per share changes basis between FY24 (₹4,452.00) and FY25 (₹7.37) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY22 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Influx Healthtech
What does Influx Healthtech do?
Influx Healthtech makes health supplements, and some skin care, herbal, pet and home care products, for other companies that put their own brand names on them. It works from factories in Palghar, Maharashtra, and its shares trade on NSE Emerge.
What is the share price of Influx Healthtech?
₹278 at the close on 19 Nov 2026, from the exchange's daily figures.
What is the market cap of Influx Healthtech?
₹644 cr at the close on 19 Nov 2026, on 2,31,50,400 shares.
What is the P/E of Influx Healthtech?
31.3 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).
What are Influx Healthtech's revenue and profit?
Revenue ₹147 cr and profit after tax ₹21 cr in FY26.
Who are the promoters of Influx Healthtech?
Munir Abdul Ganee Chandniwala, Shirin Munir Ahmed Chandniwala, Abdul Ganee Abdul Rasul Chandniwala; promoters held 73.53% at 31 March 2026.
What was the IPO price of Influx Healthtech?
₹96 a share; it listed on 25 June 2025.
What is Influx Healthtech's website?
www.influxhealthtech.com
More SME companies like Influx Healthtech
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Aptus PharmaAPPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹820 cr
- Trident LifelineTLL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹490 cr
- KRM AyurvedaKRMAYURVED · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2026Market cap ₹476 cr
- Infinium PharmachemINFINIUM · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹464 cr
- Remus PharmaceuticalsREMUS · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹937 cr
- Astonea LabsASTONEALAB · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹431 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2025 →
Built from 3 earnings call transcripts, 3 investor presentations, 2 annual reports, 1 offer document, 1 result filing, 1 press release, 83 exchange announcements, 3 shareholding patterns and 5 years of reported results. Every figure carries its source; where the documents are silent, the page says so.